Edmondo Robinson named chief digital innovation officer at Moffitt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Edmondo Robinson was named senior vice president and chief digital innovation officer at Moffitt Cancer Center.

Robinson, who brings over 16 years of clinical and technology experience to Moffitt, will oversee Moffitt’s portfolio of digital innovation, including the development and commercialization of health products, tools and technology. With this new role, Moffitt aims to create and test new services, programs, partnerships and technologies that leverage digital innovations, while challenging the status quo to reduce the cost of care, improve quality, increase access to care and enhance the patient experience.

Previously, Robinson was the chief transformation officer and senior vice president of consumerism at ChristianaCare, where he was responsible for the transformation of health care delivery to advance population health initiatives and the move from volume-based to value-based care.

Robinson is an associate professor of medicine at Thomas Jefferson University’s Sidney Kimmel Medical College. He holds a medical degree from UCLA; an MBA from The Wharton School of the University of Pennsylvania; and a master’s degree in health policy research also from the University of Pennsylvania.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login